NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD
Go back to NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD| AbbVie (NYSE: ABBV) | Delayed: 230.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $230.01 | 52 Week Low | $50.71 | |||
| Day High | $230.01 | P/E | 49.89 | |||
| Day Low | $230.01 | EPS | $4.61 | |||
| Volume | 2,754 | |||||
| (NASDAQ: LABP) | Delayed: 22.93 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.93 | 52 Week High | $ | |||
| Open | $5.45 | 52 Week Low | $ | |||
| Day High | $22.93 | P/E | N/A | |||
| Day Low | $22.93 | EPS | $ | |||
| Volume | 1,124,166 | |||||
